3 Things In Biotech, May 7: Novartis Thyroid Breakout, Redhill's Stomach Bugs, Intra-Cellular Update On Schizoid Drugs

|
Includes: ITCI, NVS, RDHL
by: Zach Hartman
Summary

Novartis scores a new approval for their MEK combo in thyroid cancer.

Redhill digs into stomach bugs.

Intra-Cellular to divulge new schizophrenia data.

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious.

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.

Novartis scores a new approval for their MEK combo in thyroid cancer

Company: Novartis (NVS)

Therapy: Dabrafenib and trametinib

Disease: Thyroid cancer

News: The FDA announced that they have granted approval for the use of the Raf/MEK inhibitors dabrafenib and trametinib for the treatment of anaplastic thyroid cancer that is unresectable or metastatic. This approval requires that the tumor test positive for a BRAF mutation. This marks the third tumor type approved for this drug combination, after melanoma and non-small cell lung cancer.

Looking forward: I don't follow the Raf/MEK inhibitor field incredibly closely, so this news took me by surprise. I had not personally realized that the FDA was reviewing this application for approval, so this is interesting news! It's also welcome, as across thyroid cancers there is a dearth of effective treatment options, and in particular this form of the disease has a notably poor prognosis and rapid course.

Good news for the continuing buildup of the dabrafenib/trametinib force.

Redhill digs into stomach bugs

Company: Redhill Biopharma (RDHL)

Therapy: RHB-105

Disease: Helicobacter pylori infection

News: RDHL announced that they have enrolled almost three quarters of the 444 patients they are targeting in the phase 3 ERADICATE Hp2 study, which is assessing the use of the combo drug RHB-105 for the treatment of Helicobacter pylori infection. This study is intended to confirm the findings from ERADICATE Hp, which showed superiority for the drug over historical controls.

Looking forward: H. pylori remains an important cause of stomach cancer, particularly outside the United States. In all, some 50% of the world's population is infected with this bacterium, so it is important for us to develop new tools to help combat it. In the case of RDHL's product, it is the combination of 2 different antibiotics, in addition to a proton pump inhibitor, tackling the infection and the complications of the infection at the same time. Hopefully, this enrollment news signals rapid progress for the trial, and perhaps a regulatory filing in early 2019.

Intra-Cellular to divulge new schizophrenia data

Company: Intra-Cellular Therapies (ITCI)

Therapy: Lumateperone

Disease: Schizophrenia

News: ITCI announced that they will present an update to their open-label safety switching study investigating lumateperone in patients with schizophrenia at the 2018 APA Annual Meeting. In the press release, the company divulged that they observed significant improvements in body weight and lab findings compared with baseline upon switching to lumateperone, which worsened when switching back to standard-of-care antipsychotics.

Looking forward: This is a favorable look at rather early data that helps to bolster the exploration of this agent. Certainly, it is not enough on its own to get approval, but the mental disorders are notoriously challenging treatment areas, so I'll take whatever I can get when it comes to these diseases.

This may signal an important up-and-comer in the mental health space.

Author's note: Thank you for taking some time out of your day to read some commentary on recent biotech happenings. I hope you'll consider leaving a comment or a question in the section below! This is one way in which Seeking Alpha is able to gauge the effectiveness of its writers and the platform. So if you want to keep seeing more editions of "3 Things," go ahead and participate!

As I mentioned above, I am now collaborating with Avisol Capital Partners on their Marketplace service known as the Total Pharma Tracker (TPT). Some of my work will be available to TPT subscribers either exclusively, or in advance. I will also collaborate in developing watchlists and other investment essentials. Please subscribe to TPT by clicking on this link - Total Pharma Tracker.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.